恒瑞医药(600276.SH)：注射用SHR-A2009获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-A2009, an antibody-drug conjugate targeting HER3 [1] Group 1 - SHR-A2009 specifically binds to HER3 on the surface of tumor cells, leading to internalization and transport to lysosomes, where it releases free toxins to kill tumor cells [1]